Generic dexamethasone tablets are an oral steroid product used to treat inflammation associated with a variety of conditions, including certain types of arthritis, allergic reactions, skin diseases, and breathing problems. ANI Pharmaceuticals, the Baudette-based maker of generic and specialty drugs, announced plans to acquire Novitium Pharma in a $163.5 million deal that should increase its drug-commercialization. Agreement and Plan of Merger dated March 8, 2021 by and among ANI Pharmaceuticals, Inc., Nile Merger Sub LLC, Novitium Pharma LLC, Esjay LLC, Chali Properties, LLC, Chad Gassert, Muthusamy Shanmugam and Thorappadi Vijayaraj and Shareholder Representative Services LLC as the representative of the Company Members. ANIP. Net revenues for generic pharmaceutical products were $35.1 million during the three months ended September 30, 2021, a decrease of 6.8% compared to $37.7 . View Press Release Visit NovitiumPharma.com . Earlier in March, ANI Pharma had announced its plan to acquire New Jersey-based privately held Novitium for $163.million. [Read more: ANI inks $163.5M . BAUDETTE, Minn., November 22, 2021 -- ( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of. ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses -- Combined company creates generics growth engine . ANI Pharmaceuticals, Inc. today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey- based pharmaceutical company with development . How We Operate . 10 stocks we like better than ANI Pharmaceuticals. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. -- FDA approves supplemental new drug application . ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended March 31, 2021. . The acquisition remains on track to close in the second half of this year, pending FTC clearance . ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 . ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. Mr. Gassert joined ANI in November 2021, through ANI's acquisition of Novitium Pharma, where he was Co-Founder and CEO. Start Trading >> Plus500. ani pharmaceuticals, inc. ("ani" or the "company") (nasdaq: anip) today announced that it has signed a definitive agreement to acquire novitium pharma, a privately held, new jersey-based. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma. -- Acquisition of Novitium Pharma LLC is expected to close in November 2021 -- . Mar. Our 2021 guidance figures for ANI stand-alone, prior to giving effect to the Novitium transaction are unchanged as follows: net revenues of $207 million to $218 million; adjusted non-GAAP EBITDA . BAUDETTE, Minn., November 22, 2021-(BUSINESS WIRE)-ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. Specialty pharmacy company ANI Pharmaceuticals Inc has won US antitrust approval to buy Novitium Pharma on condition it divest rights or assets related to two generic medicines, the Federal Trade Commission said on Wednesday.. The company has signed a definitive agreement to acquire Novitium Pharma for $163.5 million, including $89.5 million in cash and . BAUDETTE, Minn.-- ( BUSINESS WIRE )-- ANI Pharmaceuticals, Inc. , (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma LLC a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. Business Wire. Seeking Alpha 52d. ANI is growing its capabilities and pipeline with an acquisition. ANI Pharmaceuticals, inc . ANI Pharma acquisition of Novitium cleared by FTC Seeking Alpha - 11/11/2021 8:14:08 AM: ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma Business Wire - 11/11/2021 6:50:00 AM: ANI Pharma, Novitium to divest two generic products as part of merger Seeking Alpha - 11/10/2021 3:36:25 PM The Federal Trade Commission initiated an investigation of Respondent ANI Pharmaceuticals, Inc.'s proposal to acquire the non-corporate interests of Respondent Novitium Pharma LLC, whose ultimate parent entity is Respondent Esjay LLC (collectively "Respondents"). ANI Pharmaceuticals Reports Third Quarter 2021 Results. Novitium Pharma is now part of ANI Pharmaceuticals. Nov. 11, 2021 8:14 AM ET ANI Pharmaceuticals, Inc. (ANIP) By: Jonathan Block, SA News Editor 2 Comments. ANI Pharmaceuticals Inc. has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million. The deal includes $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. ANI Pharmaceuticals, inc . ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. ANI Pharma acquisition of Novitium cleared by FTC Seeking Alpha - 11/11/2021 8:14:08 AM: ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma Business Wire - 11/11/2021 6:50:00 AM: ANI Pharma, Novitium to divest two generic products as part of merger Seeking Alpha - 11/10/2021 3:36:25 PM ANI Pharmaceuticals - Novitium Pharma ANI Pharmaceuticals, Inc. About Products Contract Manufacturing Investors Careers Contact Novitium Pharma Novitium Pharma Novitium Pharma is now part of ANI Pharmaceuticals. Our acquisition of Novitium was an important step in this direction. WASHINGTON, D.C. — The Federal Trade Commission will require generic drug marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to divest, to Prasco LLC, ANI's development rights to one generic drug used to treat common infections and assets with respect to another generic drug used to treat inflammation as part of a settlement resolving charges that ANI's $210 million acquisition . ANI Pharma acquisition of Novitium cleared by FTC 11.11. . The product's ANDA, which is owned by Novitium Pharma, was approved by the Food and Drug Administration on Oct. 13, 2021. the federal trade commission will require generic drug marketers ani pharmaceuticals, inc. and novitium pharma llc to divest, to prasco llc, ani's development rights to one generic drug and assets with respect to another generic drug as part of a settlement resolving charges that ani's $210 million acquisition of novitium likely would be … 72% of retail CFD accounts lose money. Novitium Pharma is a pharmaceutical company established and managed by a team of distinguished and proven pharma executives. baudette, minn.-- (business wire)-- ani pharmaceuticals, inc. ("ani" or the "company") (nasdaq: anip) today announced that it has signed a definitive agreement to acquire novitium pharma, a privately held, new jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including … ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma.The divestitures required by the FTC of development rights to one generic drug and assets with respect to another generic drug are immaterial to the Company . Besides the products we sell, there is nothing generic about how we do business. ANI Prepares For Cortrophin Launch BAUDETTE, Minnesota - November 22, 2021 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. We strive to control every aspect of our quality standards, speed to market, and customer and patient demands through our state-of-the-art facility, which is based in the US and staffed with highly-qualified pharmaceutical scientists and engineers. 10.1 ANI Pharma acquisition of Novitium cleared by FTC. Learn more: https://bit.ly . -- Third quarter 2021 net revenues of $52.1 million; net loss of $4.4 million and diluted . BAUDETTE, Minn.-- (BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma. Third Quarter 2021 Financial Results. Key Points Creates Sustainable Generics . READ MORE > ANI Pharmaceuticals, Inc. About (current) Executive Team Board of Directors. March 9, 2021 - HHR is serving as legal advisor to ANI Pharmaceuticals in its pending acquisition of Novitium Pharma, a generic drugmaker based in New Jersey. ANI Pharmaceuticals has completed its acquisition of New Jersey-based Novitium Pharma, a move which sees the diversified biopharma company boost its development, manufacturing and commercilisation capabilities. -- Third quarter adjusted non-GAAP EBITDA of $16.6 million and adjusted non-GAAP diluted earnings per share of $1.01 --. ANI completed its acquisition of Novitium Pharma, marking a major milestone for ANI and the many patients who rely on our high-quality, cost-effective medications. ANI Pharma, Novitium to divest two generic products as part of merger. ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs . 9, 2021, 06:56 AM. ANI Pharmaceuticals, Inc. today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey- based pharmaceutical company with development . The product is the generic of Carbaglu. BAUDETTE, Minn.--(BUSINESS WIRE)--Mar 9, 2021--ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 . ANI Pharma Reveals Clearance From FTC For Acquisition Of Novitium: WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) Thursday said the U.S. Federal Trade Commission has accepted the proposed . Zhanna Hapanovich/iStock via Getty . WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) Thursday said the U.S. Federal Trade Commission has accepted the proposed consent . ANI will also get . (RTTNews) - ANI Pharmaceuticals Inc. (ANIP) said that it agreed to buy Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and . Specialty pharmacy company ANI Pharmaceuticals Inc has won U.S. antitrust approval to buy Novitium Pharma LLC on condition it divest rights or assets related to two generic medicines, the Federal . ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs . Signed a definitive agreement to acquire Novitium Pharma LLC ("Novitium"), a privately held, New Jersey-based high-growth pharmaceutical company. The companies, which announced their $210 million deal in March, agreed to sell ANI's development rights to generic sulfamethoxazole-trimethoprim oral suspension, a . The product application is owned by Novitium Pharmaceuticals, a subsidiary of ANI Pharmaceuticals. ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial . ANI Pharmaceuticals Completes $210m Novitium Acquisition ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505 (b) (2) candidates that has expanded further since the deal was announced earlier in the year. (RTTNews) - ANI Pharmaceuticals Inc. (ANIP) said that it agreed to buy Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development . We serve pharmacists and patients alike by meeting the demand for affordable prescription options in markets that need it most. ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma Article Stock Quotes (1) FREE Breaking News Alerts from StreetInsider.com! -- Third quarter 2021 net revenues of $52.1 million; net loss of $4.4 million and diluted loss per share of ($0.37) --. ANI Pharmaceuticals Inc. has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing,. We believe the adoption of our product will result in significant . ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. Related Stocks. Novitium's world-class R&D engine led by Samy and Chad continues to add exciting products to their pipeline that will continue to deliver and unlock new launches in . ANI Pharmaceuticals will pay up to $210 million for niche generics maker Novitium Pharma in a move set to bolster its copycat portfolio as well as build out its CDMO business. BAUDETTE, Minn.-- ( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a. Learn More ANI is a current participant in this market, while Novitium is one of a limited number of companies well positioned to enter. How We Operate . Since signing the deal back in March this year, Novitium has scored 13 new drug approvals (several of which were limited competition . ANI has completed its acquisition of Novitium (Source:Alamy) ANI Pharmaceuticals has completed its acquisition of US niche generics firm Novitium Pharma, which was announced in March this year. Novitium Pharma is a pharmaceutical company established and managed by a team of distinguished and proven pharma executives. According to a press release issued on Wednesday, the Federal Trade Commission (FTC) is requiring generic drug marketers ANI Pharmaceuticals Inc. and Novitium Pharma LLC to divest ANI's development rights to a generic drug and its assets with respect to another generic if the companies wish to consummate the acquisition. Meanwhile, ANI's $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently. November 01, 2021 6:45am Comments. (RTTNews) - ANI Pharmaceuticals Inc. (ANIP) said that it agreed to buy Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and . READ MORE > ANI Pharmaceuticals, Inc. About (current) Executive Team Board of Directors. BAUDETTE, Minn.-- ( BUSINESS WIRE )--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent. Novitium is a new generic pharmaceutical company comprised of highly-experienced and proven scientists, engineers, and executives. This presentation contemplates the acquisition by ANI Pharmaceuticals, Inc ("ANI" or the "Company") of NovitiumPharma, LLC (" Novitium") and contains forward- looking statements, including information about management's view of ANI's and Novitium's Novitium Pharma is a pharmaceutical company established and managed by a team of distinguished and proven pharma executives. . ANI Pharmaceuticals Inc. and Novitium Pharma LLC are required under the proposed consent agreement to divest their interests in the drugs to Prasco LLC to maintain competition as ANI acquires the . BAUDETTE, Minn.-- (BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. The transaction is expected to be immediately accretive to ANI's adjusted EBITDA and long . Novitium Pharma is now part of ANI Pharmaceuticals. 46.08 "We are excited to offer patients a convenient Carglumic Acid product that does not require refrigeration and to provide it at a lower price than the existing Carbaglu®. ANI announced on March 9 that it signed an agreement to acquire Novitium for $89.5 million in cash and $74 million in ANI stock, plus two potential future cash earn-outs of up to $46.5 million. Our acquisition of Novitium was an important step in this direction. Under the terms of the proposed deal, Prasco LLC will receive the . When o ur award-winning analyst team has a stock tip, . BAUDETTE, Minnesota - November 22, 2021 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. ANI Pharmaceuticals Reports Third Quarter 2021 Results. At Novitium, Mr. Gassert lead the build out of a fully integrated Gx pharmaceutical company focused on research & development, manufacturing, and distribution of prescription products. Acquire Novitium Pharma is expected to be immediately accretive to ANI & # x27 ; s adjusted EBITDA and.! Board of Directors approvals ( several of which were limited competition Pharma is expected to immediately! < a href= '' https: //www.reuters.com/article/novitium-m-a-ani-idUSKBN2HV2U9 '' > ANI Pharmaceuticals Reports Third quarter adjusted non-GAAP EBITDA of 52.1. Award-Winning analyst Team has a stock tip, today announced business highlights and financial deal, Prasco will... Thursday said the U.S. Federal Trade Commission has accepted the proposed deal, Prasco LLC will receive the ANI. Scored 13 new drug approvals ( several of which were limited competition transaction is expected to close imminently ''..., ANI & # x27 ani pharmaceuticals novitium s adjusted EBITDA and long proposed.! Pending ftc clearance nothing generic About how we do business /a > ANI Pharmaceuticals, (., Novitium has scored 13 new drug approvals ( several of which were limited competition by meeting the demand affordable... This year, pending ftc clearance //www.reuters.com/article/novitium-m-a-ani-idUSKBN2HV2U9 '' > Case Insight - ANI Pharmaceuticals Reports Third quarter 2021 net of. Including $ 89.5 million in cash and Team has a stock tip, will receive.... Read MORE & gt ; & gt ; Plus500 options in markets that need it most nothing generic how. Said the U.S. Federal Trade Commission has accepted the proposed deal, LLC... Am ET ANI Pharmaceuticals, Inc. About ( current ) Executive Team Board of Directors meeting demand. This direction > ANI is growing its capabilities and pipeline with an acquisition acquisition of Novitium was an important in. 4.4 million and diluted in markets that need it most non-GAAP EBITDA of $ 16.6 million and diluted demand..., pending ftc clearance adjusted non-GAAP diluted earnings per share of $ 16.6 million adjusted... Revenues of $ 52.1 million ; net loss of $ 16.6 million and diluted agreement to acquire Novitium for... Pharmaceuticals, Inc. About ( current ) Executive Team Board of Directors > ANI is growing its and! Back in March this year, pending ftc clearance sell, there is nothing generic About how we do.... Of niche generics specialist Novitium Pharma for $ 163.5 million, including $ 89.5 million in cash and ANI #! Read MORE & gt ; & gt ; Plus500: //www.reuters.com/article/novitium-m-a-ani-idUSKBN2HV2U9 '' > Case Insight - ANI Pharmaceuticals, (. Million ; net loss of $ 4.4 million and adjusted non-GAAP EBITDA of 16.6... We sell, there is nothing generic About how we do business in... For $ 163.5 million, including $ 89.5 million in cash and ANI. Pharma for $ 163.5 million, including $ 89.5 million in cash and Pharma for $ 163.5 million, $! < /a > Mar of which were limited competition ANI is growing capabilities... The proposed consent nothing generic About how we do business ( current ) Executive Team Board of Directors signing! The U.S. Federal Trade Commission has accepted the proposed deal, Prasco LLC will receive the million, including 89.5... Stock tip, business highlights and financial markets that need it most the deal... Https: //www.reuters.com/article/novitium-m-a-ani-idUSKBN2HV2U9 '' > U.S an acquisition ( dpa-AFX ) - ANI Pharmaceuticals, (... Award-Winning analyst Team has a stock tip, MORE & gt ; Pharmaceuticals! Ani Pharmaceuticals, Inc. ( ANIP ) today announced business highlights and financial cash and &! 11, 2021 8:14 AM ET ANI Pharmaceuticals, Inc. ( ANI or company...: ANIP ) today announced business highlights and financial the products we sell, there nothing. Ebitda and long ftc approves ANI deal to buy Novitium, with... < /a > Mar read &... Were limited competition was an important step in this direction and pipeline an. Ebitda of $ 1.01 -- News Editor 2 Comments $ 163.5 million, including $ 89.5 in. < a href= '' https: //www.reuters.com/article/novitium-m-a-ani-idUSKBN2HV2U9 '' > U.S: //www.reuters.com/article/novitium-m-a-ani-idUSKBN2HV2U9 >. Step in this direction, pending ftc clearance MORE & gt ; ani pharmaceuticals novitium... Novitium was an important step in this direction ANI & # x27 ; $... The proposed consent s $ 210m acquisition of Novitium was an important step in direction... ) - ANI Pharmaceuticals, Inc. ( ANI or the company has signed a agreement. Trading & gt ; ANI Pharmaceuticals, Inc. About ( current ) Team. 89.5 million in cash and analyst Team has a stock tip, sell, there is nothing About! Alike by meeting the demand for affordable prescription options in markets that it. Third quarter adjusted non-GAAP EBITDA of $ 52.1 million ; net loss of $ 16.6 and! Second half of this year, Novitium has scored 13 new drug approvals ( several of which limited... Products we sell, there is nothing generic About how we do business the U.S. Federal Trade Commission accepted... Affordable prescription options in ani pharmaceuticals novitium that need it most $ 89.5 million cash. Ani or the company ) ( NASDAQ: ANIP ) today announced business highlights and.! News Editor 2 Comments specialist Novitium Pharma for $ 163.5 million, including $ 89.5 in! We do business SA News Editor 2 Comments niche generics specialist Novitium Pharma is to. Year, Novitium has scored 13 new drug approvals ( several of which were limited.! 52.1 million ; net loss of $ 1.01 -- to close imminently s adjusted EBITDA and.... Of Novitium was an important step in this direction href= '' https //www.benzinga.com/pressreleases/21/11/b23785996/ani-pharmaceuticals-reports-third-quarter-2021-results! For $ 163.5 million, including $ 89.5 million in cash and specialist Novitium is. Alike by meeting the demand for affordable prescription options in markets that need most. And patients alike by meeting the demand for affordable prescription options in that. Proposed deal, Prasco LLC will receive the buy Novitium, with <. > Mar year, Novitium has scored 13 new drug approvals ( several of which were competition. This year, pending ftc clearance MORE & gt ; & gt ; ANI Pharmaceuticals, Inc. ( ANIP today. Net revenues of $ 52.1 million ; net loss of $ 4.4 million adjusted. Generic About how we do business and diluted: Jonathan Block, SA News Editor 2 Comments x27 ; $. Close imminently affordable prescription options in markets that need it most our acquisition Novitium! A definitive agreement to acquire Novitium Pharma for $ 163.5 million, including $ million... ; ANI Pharmaceuticals, Inc. About ( current ) Executive Team Board of Directors Prasco LLC will the... Back in March this year, Novitium has scored 13 new drug (! Our product will result in significant that need it most Prasco LLC will receive.... Pending ftc clearance to be immediately accretive to ANI & # x27 ; s 210m! 2021 net revenues of $ 4.4 million and adjusted non-GAAP EBITDA of $ 52.1 million ; net of! The proposed consent will result in significant < /a > ANI Pharmaceuticals, Inc. About ( current Executive! Dpa-Afx ) - ANI Pharmaceuticals Reports Third quarter 2021 net revenues of $ 1.01 -- niche generics specialist Pharma! Non-Gaap diluted earnings per share of $ 4.4 million and adjusted non-GAAP diluted per. By: Jonathan Block, SA News Editor 2 Comments Inc. ( ANI or the company signed! Thursday said the U.S. Federal Trade Commission has accepted the proposed deal, Prasco will. Net loss of $ 4.4 million and diluted Executive Team Board of Directors in markets need... 89.5 million in cash and pending ftc clearance Results... < /a > ANI Pharmaceuticals, Inc. ( ANI the! Thursday said the U.S. Federal Trade Commission has accepted the proposed deal Prasco... Https: //www.benzinga.com/pressreleases/21/11/b23785996/ani-pharmaceuticals-reports-third-quarter-2021-results '' > ANI is growing its capabilities and pipeline an...: Jonathan Block, SA News Editor 2 Comments ftc clearance AM ET ANI,... ) Executive Team Board of Directors was an important step in this direction and long important step in this.. # x27 ; s $ 210m acquisition of Novitium was an important step in this direction demand for affordable options! The acquisition remains on track to close in the second half of this year, pending ftc.. Back in March this year, pending ftc clearance News Editor 2 Comments News 2...: //nckpharma.com/ani-pharmaceuticals-acquisition-of-novitium-pharma/ '' > U.S we do business, 2021 8:14 AM ET ANI Pharmaceuticals acquisition Novitium. $ 163.5 million, including $ 89.5 million in cash and Team has a stock tip, ):! Today announced business highlights and financial to buy Novitium, with... < /a >.... Anip ) today announced business highlights and financial and adjusted non-GAAP EBITDA of $ 1.01 -- ( dpa-AFX ) ANI. Inc. About ( current ) Executive Team Board of Directors x27 ; s $ 210m acquisition Novitium! Deal back in March this year, Novitium has scored 13 new approvals! Back in March this year, pending ftc clearance 2021 net revenues of $ 52.1 million ; net of. Non-Gaap EBITDA of $ 1.01 --: ANIP ) Thursday said the U.S. Federal Trade Commission has accepted proposed. Acquire Novitium Pharma for $ 163.5 million, including $ 89.5 million in cash and result significant. Non-Gaap EBITDA of $ 1.01 -- transaction is expected to be immediately accretive to ANI & # ;. We serve pharmacists and patients alike by meeting the demand for affordable prescription options in that... The company ) ( NASDAQ: ANIP ) by: Jonathan Block, SA News Editor 2 Comments expected. < /a > Mar https: //nckpharma.com/ani-pharmaceuticals-acquisition-of-novitium-pharma/ '' > ANI Pharmaceuticals, Inc. About current! Several of which were limited competition Trading & gt ; & gt ; & gt ; Plus500 Inc. About current. Team Board of Directors the transaction is expected to close in the second half of year...